Quarterly report [Sections 13 or 15(d)]

OPERATING SEGMENT (Details)

v3.25.1
OPERATING SEGMENT (Details)
3 Months Ended
Mar. 31, 2025
USD ($)
segment
Mar. 31, 2024
USD ($)
SEGMENT INFORMATION    
Number of operating segments | segment 1  
Number of reportable segments | segment 1  
Research and development:    
Segment and consolidated net loss $ 6,604,029 $ 26,641,983
Single reportable segment    
Research and development:    
Phase 2 study in WM 633,000 2,194,000
Phase 1 study in pediatric tumors 733,000 499,000
Manufacturing and related costs 709,000 3,313,000
Pre-clinical projects costs 507,000 21,000
General research and development costs 845,000 1,061,000
General and administrative 2,974,000 4,913,000
Other segment items 203,000 14,641,000
Segment and consolidated net loss $ 6,604,000 $ 26,642,000
Other segment items, description Other segment items consist of warrant issuance expense, (gain) loss on valuation of warrants, and interest income. Other segment items consist of warrant issuance expense, (gain) loss on valuation of warrants, and interest income.